- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- August 2024
- 123 Pages
China
From €1576EUR$1,800USD£1,368GBP
- Report
- August 2024
- 244 Pages
China
From €3503EUR$4,000USD£3,041GBP
Leuprorelin Acetate is a synthetic hormone used in the treatment of prostate and breast cancer. It is a gonadotropin-releasing hormone agonist (GnRH agonist) that works by blocking the production of testosterone and estrogen, which can slow the growth of certain types of cancer. It is administered as an injection or implant and is often used in combination with other cancer treatments such as chemotherapy and radiation therapy.
Leuprorelin Acetate is a widely used drug in oncology, with a range of applications in the treatment of prostate and breast cancer. It is also used to treat endometriosis, uterine fibroids, and precocious puberty.
The market for Leuprorelin Acetate is highly competitive, with a number of major pharmaceutical companies offering the drug. These include Pfizer, Novartis, Sanofi, and Takeda. Show Less Read more